Trial Profile

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolododekin alfa (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms ANCHOR
Sponsors Ankyra Therapeutics

Most Recent Events

18 Jul 2025 Planned number of patients changed from 107 to 97.
18 Jul 2025 Planned End Date changed from 1 Jan 2026 to 1 Jun 2027.
18 Jul 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com